ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2017
Investment Success in Public Health: An Analysis of the Cost-Effectiveness and Cost-Benefit of the Global Programme to Eliminate Lymphatic Filariasis.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Economic evaluations of onchocerciasis interventions: a systematic review and research needs.Tropical medicine & international health : TM & IH · 2019Pooled it
- Economic Evaluations of Mass Drug Administration: The Importance of Economies of Scale and Scope.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018Pooled it
- Economic evaluations of lymphatic filariasis interventions: a systematic review and research needs.Parasites & vectors · 2018Pooled it
- Jaboulay's technique contrasted with a novel hydrocelectomy technique using a vessel sealer in the treatment of adult hydrocele: a prospective randomized study.International urology and nephrology · 2020Trial
- Neglected tropical diseases elimination activities in South Sudan's largest refugee camp: lessons from 2 years of work.International health · 2026Article
- Public health surveillance of tropical diseases in Madagascar: a scoping review of population burden, intervention strategies, and health system responses.BMC public health · 2025Article
- Current perspectives in the epidemiology and control of lymphatic filariasis.Clinical microbiology reviews · 2025Review
- Reducing the Antigen Prevalence Target Threshold for Stopping and Restarting Mass Drug Administration for Lymphatic Filariasis Elimination: A Model-Based Cost-effectiveness Simulation in Tanzania, India and Haiti.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Review
- A Comparative Study of Lymphatic Filariasis-Related Perceptions among Treated and Non-Treated Individuals in the Ahanta West Municipality of Ghana.Tropical medicine and infectious disease · 2022Article
- A refined and updated health impact assessment of the Global Programme to Eliminate Lymphatic Filariasis (2000-2020).Parasites & vectors · 2022Article
- Costs of mass drug administration for scabies in Fiji.PLoS neglected tropical diseases · 2022Article
- Effectiveness of community-based burden estimation to achieve elimination of lymphatic filariasis: A comparative cross-sectional investigation in Côte d'Ivoire.PLOS global public health · 2022Article
- The implementation and impact of a pilot hydrocele surgery camp for LF-endemic communities in Ethiopia.PLoS neglected tropical diseases · 2021Article
- Are current preventive chemotherapy strategies for controlling and eliminating neglected tropical diseases cost-effective?BMJ global health · 2021Review
- Medicine donation programmes supporting the global drive to end the burden of neglected tropical diseases.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2021Article
- Economic evaluations addressing diagnosis and treatment strategies for neglected tropical diseases: an overview.Revista do Instituto de Medicina Tropical de Sao Paulo · 2021Review
- Health economic analyses of the Global Programme to Eliminate Lymphatic Filariasis.International health · 2020Article
- The role of medicine donations in the global programme for the elimination of lymphatic filariasis.International health · 2020Article
- The Health and Economic Burdens of Lymphatic Filariasis Prior to Mass Drug Administration Programs.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Background: It has been estimated that $154 million per year will be required during 2015-2020 to continue the Global Programme to Eliminate Lymphatic Filariasis (GPELF). In light of this, it is important to understand the program's current value. Here, we evaluate the cost-effectiveness and cost-benefit of the preventive chemotherapy that was provided under the GPELF between 2000 and 2014. In addition, we also investigate the potential cost-effectiveness of hydrocele surgery. Methods: Our economic evaluation of preventive chemotherapy was based on previously published health and economic impact estimates (between 2000 and 2014). The delivery costs of treatment were estimated using a model developed by the World Health Organization. We also developed a model to investigate the number of disability-adjusted life years (DALYs) averted by a hydrocelectomy and identified the cost threshold under which it would be considered cost-effective. Results: The projected cost-effectiveness and cost-benefit of preventive chemotherapy were very promising, and this was robust over a wide range of costs and assumptions. When the economic value of the donated drugs was not included, the GPELF would be classed as highly cost-effective. We projected that a typical hydrocelectomy would be classed as highly cost-effective if the surgery cost less than $66 and cost-effective if less than $398 (based on the World Bank's cost-effectiveness thresholds for low income countries). Conclusions: Both the preventive chemotherapy and hydrocele surgeries provided under the GPELF are incredibly cost-effective and offer a very good investment in public health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.